Coherus BioSciences, Inc. financial data

Symbol
CHRS on Nasdaq
Location
C/O Dennis M. Lanfear, 333 Twin Dolphin Dr, Suite 600, Redwood City, CA
Fiscal year end
December 31
Latest financial report
8-K - Q4 2024 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 127 % +2.02%
Quick Ratio 1.22 % -88.6%
Debt-to-equity -1.75K % -159%
Return On Assets 34.9 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 121M shares +4.91%
Common Stock, Shares, Outstanding 116M shares +0.89%
Entity Public Float 171M USD -47.4%
Common Stock, Value, Issued 12K USD 0%
Weighted Average Number of Shares Outstanding, Basic 116M shares +0.89%
Weighted Average Number of Shares Outstanding, Diluted 116M shares +0.89%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 98.7M USD +17.3%
Costs and Expenses 218M USD +142%
Operating Income (Loss) -181M USD +23.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -182M USD +22.4%
Income Tax Expense (Benefit) -380K USD
Net Income (Loss) Attributable to Parent 155M USD -230%
Earnings Per Share, Basic 1 USD/shares +3175%
Earnings Per Share, Diluted 1 USD/shares +3175%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 103M USD +5.8%
Marketable Securities, Current 88.3M USD
Inventory, Net 2.05M USD -95.7%
Assets, Current 461M USD +24.9%
Property, Plant and Equipment, Net 1.63M USD -43.9%
Operating Lease, Right-of-Use Asset 4.52M USD -23.6%
Intangible Assets, Net (Excluding Goodwill) 71.7M USD +1108%
Goodwill 943K USD 0%
Other Assets, Noncurrent 4.45M USD -39.7%
Assets 517M USD +2.28%
Accounts Payable, Current 24.9M USD +13.7%
Employee-related Liabilities, Current 13.4M USD -15%
Accrued Liabilities, Current 13.1M USD -78.5%
Liabilities, Current 372M USD +26%
Deferred Income Tax Liabilities, Net 1.1M USD 0%
Operating Lease, Liability, Noncurrent 3.29M USD -34%
Other Liabilities, Noncurrent 17.5M USD -39.8%
Liabilities 429M USD -27.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -203K USD +26.2%
Retained Earnings (Accumulated Deficit) -1.35B USD +10.3%
Stockholders' Equity Attributable to Parent 87.8M USD
Liabilities and Equity 517M USD +2.28%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -25.8M USD +44.8%
Net Cash Provided by (Used in) Financing Activities -264K USD -130%
Net Cash Provided by (Used in) Investing Activities -17.5M USD -109%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 116M shares +0.89%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -43.6M USD -128%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 104M USD +5.76%
Deferred Tax Assets, Valuation Allowance 413M USD -2.49%
Deferred Tax Assets, Gross 419M USD -2.57%
Operating Lease, Liability 4.98M USD -22.2%
Payments to Acquire Property, Plant, and Equipment 152K USD -75.3%
Lessee, Operating Lease, Liability, to be Paid 5.85M USD -26.4%
Operating Lease, Liability, Current 1.69M USD +18.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.13M USD -3.01%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.19M USD +4.63%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 871K USD -43.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.53M USD -28%
Deferred Tax Assets, Operating Loss Carryforwards 158M USD -7.23%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 19.2M USD +10.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.53M USD +424%
Additional Paid in Capital 1.43B USD +1.47%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 2.7M USD -36.4%
Depreciation, Depletion and Amortization 1.1M USD +37.5%
Deferred Tax Assets, Net of Valuation Allowance 6.32M USD -7.65%
Share-based Payment Arrangement, Expense 20.6M USD -36.2%
Interest Expense 7.48M USD -17.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%